| Boston Children’s Hospital | David Williams | Phase 2 Study of Hematopoietic Stem Cell Gene Transfer Inducing Fetal Hemoglobin in Sickle Cell Disease |
$8,333,581 |
| University of California, San Francisco | Mark C. Walters M.D. | Transplantation of CRISPR-CAS9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease |
$8,389,407 |
| ExCellThera Inc. | Dr Pierre Caudrelier | A Phase 1 Study of ECT-001 Expanded Cord Blood and Myeloablative Regimen with Reduced Toxicity in Patients with Severe Sickle Cell Disease. |
$600,000 |
